National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 58160-58161 [2019-23641]
Download as PDF
<![CDATA[
58160
Federal Register / Vol. 84, No. 210 / Wednesday, October 30, 2019 / Notices
The collection of information for FDA
adverse event reporting and electronic
submissions using the Electronic
Submission Gateway and the Safety
Reporting Portal has been approved
under OMB control number 0910–0645.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at either
https://www.fda.gov/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/default.htm,
https://www.fda.gov/Biologics
BloodVaccines/GuidanceCompliance
RegulatoryInformation/default.htm, or
https://www.regulations.gov.
Dated: October 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–23666 Filed 10–29–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–0221]
Agency Information Collection
Request; 30-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before November 29,
2019.
SUMMARY:
Submit your comments to
OIRA_submission@omb.eop.gov or via
facsimile to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Sherrette Funn, Sherrette.Funn@hhs.gov
or (202) 795–7714. When submitting
comments or requesting information,
please include the document identifier
0990–New–30D and project title for
reference.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Family
Planning Annual Report (FPAR).
Type of Collection: Renewal with
change.
OMB No.: 0990–0221.
Abstract: The Office of Population
Affairs within the Office of the Assistant
Secretary for Health is requesting an
extension on a currently approved
Family Planning Annual Report (FPAR)
data collection and reporting tool (OMB
No. 0990–0221). This annual reporting
requirement is for family planning
services delivery projects authorized
and funded by the Title X Family
Planning Program [‘‘Population
Research and Voluntary Family
Planning Programs’’ (Pub. L. 91–572)],
which was enacted in 1970 as Title X of
ADDRESSES:
the Public Health Service Act (Section
1001; 42 U.S.C. 300). The FPAR data
collection and reporting tool will
include a new module to collect
substance use disorder (SUD) screening
data in this request to extend an OMB
approval to collect essential, annual
data from Title X grantees.
Need and Proposed Use of the
Information
The Title X Family Planning Program
(‘‘Title X program’’ or ‘‘program’’) is the
only Federal grant program dedicated
solely to providing individuals with
comprehensive family planning and
related preventive health services (e.g.,
screening for breast and cervical cancer,
sexually transmitted diseases (STDs),
and human immunodeficiency virus).
By law, priority is given to persons from
low-income families (Section 1006[c] of
Title X of the Public Health Service Act,
42 U.S.C. 300). The Office of Population
Affairs (OPA) within the Office of the
Assistant Secretary for Health
administers the Title X program.
Likely Respondents: Respondents for
this annual reporting requirement are
centers that receive funding directly
from OPA for family planning services
authorized and funded under the Title
X Family
This weighted average hour burden
accounts for differences in reporting
burden by type of grantee agency
grantee (e.g., public health department
or private agency), as found in the 2009
FPAR Burden Study. For purposes of
this estimate, the average hour burden
ranges between 39 hours (public health
department) and 32 hours (private
agency).
ANNUALIZED BURDEN HOUR TABLE
Number of
respondents
Number of
responses per
respondents
Average
annualized
burden per
response
(hours)
Annualized
total burden
(hours)
Type of respondents
Form name
Grantees ...........................................
FPAR ................................................
93
1
36
3,348
Total ...........................................
...........................................................
93
1
36
3,348
Terry Clark,
Office of the Secretary, Asst Paperwork
Reduction Act Reports Clearance Officer.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2019–23675 Filed 10–29–19; 8:45 am]
National Institutes of Health
BILLING CODE 4150–34–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:18 Oct 29, 2019
Jkt 250001
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\30OCN1.SGM
30OCN1
Federal Register / Vol. 84, No. 210 / Wednesday, October 30, 2019 / Notices
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HIV Vaccines Clinical Trials
Network Leadership and Operations Center
(UM1 Clinical Trial Required).
Date: November 21, 2019.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D.,
MPH Acting Senior Scientific Review Officer,
AIDS Review Branch, Scientific Review
Program, RM 3E70, National Institutes of
Health, NIAID, 5601 Fishers Lane, MSC 9834,
Rockville, MD 20852–9834, 240–669–2081,
audrey.lau@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: November 25, 2019.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D.,
MPH Scientific Review Officer, AIDS Review
Branch, Scientific Review Program, RM 3E70,
National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9834, Rockville, MD
20852–9834 240–669–2081 audrey.lau@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 24, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23641 Filed 10–29–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
VerDate Sep<11>2014
17:18 Oct 29, 2019
Jkt 250001
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–19–
177: High-End Instrumentation (HEI) Grant
Program.
Date: November 22, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel, 1700 Tysons
Boulevard, McLean, VA 22102.
Contact Person: Songtao Liu, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5118,
Bethesda, MD 20817, 301–827–6828,
songtao.liu@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Shared
Instrumentation: Interdisciplinary Molecular
Sciences and Technologies (S10).
Date: November 22, 2019.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6046B,
MSC 7892, Bethesda, MD 20892, 301–408–
9655, gubina@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Synapses, Neurodegeneration and
Signaling.
Date: November 22, 2019.
Time: 10:15 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Vanessa S. Boyce, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 4185,
MSC 7850, Bethesda, MD 20892, (301) 402–
3726, boycevs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Tobacco Regulatory Science B.
Date: November 22, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Kristen Prentice, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3112,
MSC 7808, Bethesda, MD 20892, 301–496–
0726, prenticekj@mail.nih.gov.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
58161
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Tobacco Regulatory Science B.
Date: November 22, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Michael J. McQuestion,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
Bethesda, MD 20892, 301–480–1276,
mike.mcquestion@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Dermatology.
Date: November 22, 2019.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Aruna K. Behera, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4211,
MSC 7814, Bethesda, MD 20892, 301–435–
6809 beheraak@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Health Interventions, Nursing &
Aging.
Date: November 22, 2019.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rock Drive, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Mark Allen Vosvick, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
Bethesda, MD 20892, mark.vosvick@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Skeletal Muscle Pathobiology and
Regeneration.
Date: November 22, 2019.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Yi-Hsin Liu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7814, Bethesda, MD 20892, 301–435–
1781, liuyh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Psychosocial Risks and Disease
Prevention.
Date: November 22, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
E:\FR\FM\30OCN1.SGM
30OCN1
]]>Agencies
[Federal Register Volume 84, Number 210 (Wednesday, October 30, 2019)]
[Notices]
[Pages 58160-58161]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material,
[[Page 58161]]
and personal information concerning individuals associated with the
grant applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HIV Vaccines Clinical Trials
Network Leadership and Operations Center (UM1 Clinical Trial
Required).
Date: November 21, 2019.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D., MPH Acting Senior
Scientific Review Officer, AIDS Review Branch, Scientific Review
Program, RM 3E70, National Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9834, Rockville, MD 20852-9834, 240-669-2081,
[email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIH Support for Conferences and
Scientific Meetings (Parent R13 Clinical Trial Not Allowed).
Date: November 25, 2019.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D., MPH Scientific Review
Officer, AIDS Review Branch, Scientific Review Program, RM 3E70,
National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834,
Rockville, MD 20852-9834 240-669-2081 [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 24, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-23641 Filed 10-29-19; 8:45 am]
BILLING CODE 4140-01-P
